Speciality: Hematology
Description:
A warm welcome to all the medical professionals to this session on "Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective." This session synthesizes the key takeaways from our discussion on ferric maltol, highlighting its transformative potential in the management of iron deficiency anemia (IDA). The overarching new perspective is a shift away from the traditional, one-size-fits-all approach to oral iron supplementation, toward a more nuanced and patient-focused strategy.
The primary limitation of standard oral iron salts is their high incidence of gastrointestinal (GI) side effects, which leads to poor patient adherence and treatment failure. Ferric maltol provides a new perspective by addressing this issue directly. Its unique chemical structure, a stable complex of ferric iron (Fe³⁺) and maltol, minimizes the release of free iron in the gut, thereby reducing GI irritation and inflammation. This improved tolerability is not just a secondary benefit; it is a core feature that can lead to better treatment compliance and, ultimately, more effective iron repletion.
In conclusion, the new perspective is that ferric maltol is not simply another oral iron option, but a clinically meaningful alternative that overcomes the historical drawbacks of traditional oral iron. Its proven efficacy and favorable tolerability profile, particularly in challenging patient populations like those with inflammatory bowel disease or chronic kidney disease, position it as a valuable tool in the modern management of IDA. This allows clinicians to choose a therapy that is both effective and well-tolerated from the outset, leading to a better quality of life for patients.
See More Webinars @ Hidoc Webinars
1.
New surgical method shows promising results for cervical cancer treatment
2.
Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth
3.
GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium
4.
Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer
5.
Can Prior Authorization Be Better With Artificial Intelligence?
1.
Checkpoint Inhibitors in Oncology: Advances in PD-1/PD-L1 and CTLA-4 Targeted Therapy
2.
Public Health Strategies for Improving Cancer Survivorship Support Systems
3.
Analyzing the Mechanisms and Efficacy of Carboplatin, Abraxane, and Albumin-Bound Formulations
4.
Treating Methemoglobinemia: What You Need to Know Now!
5.
Red Cell Deformability as a Target in Critical Illness
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
2.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
3.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
5.
Updates on Standard V/S High Risk Myeloma Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation